Trastuzumab drug donation policy

Fam-trastuzumab deruxtecan-nxki, also known as Enhertu, is an antibody drug conjugate (ADC) targeting HER2 (human epidermal growth factor receptor 2). It combines anti-HER2 antibodies with cytotoxic drugs to accurately identify and attack HER2-overexpressing cancer cells. The drug has shown significant efficacy in treating HER2-positive breast cancer and other HER2-overexpressing solid tumors, providing a new treatment option for patients who have progressed on other treatments.

The drug donation policy for trastuzumab may depend on the regulations and policies of different countries, regions and medical institutions, and may also vary based on treatment needs, patient qualifications, financial status and other factors. Generally, eligible patients can receive some or all of the drug's free supply through an application process. For example, some pharmaceutical companies may cooperate with medical institutions or government departments to establish patient assistance programs. These programs may include offering drug discounts, copay assistance, free medications, etc. to reduce the financial burden on patients. In some cases, pharmaceutical companies may invite eligible patients to participate in clinical trials. Patients participating in clinical trials often receive investigational drugs and related medical services at no cost.

Therefore, the specific content and application of the trastuzumab drug donation policy may vary depending on pharmaceutical companies and regions. Patients in need should consult professional doctors or relevant institutions to obtain the most accurate and up-to-date information. At the same time, patients and family members should also understand the efficacy and possible risks of drugs in order to make treatment choices that suit them.